Shantha Biotech, a part of Sanofi, is planning to raise its production capacity at the Hyderabad facility.
Sanofi has earmarked $300 million (approx Rs 270 crore) to set up new vaccine manufacturing unit in India over the next three years, as well as for augmenting capacities at the existing facility. Shantha will be investing in training people on technical and quality aspects, improving quality standards, upgrading infrastructure etc.
The company is expected to introduce the rotavirus vaccine to the market by 2015. Currently, the rotavirus vaccine, developed by Shantha, is in an early stage of clinical trials. The company is also planning to relaunch the pentavalent Shan5 vaccine by December 2013.